Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry.

Clin Genitourin Cancer 2022 Apr 9. Epub 2022 Apr 9.

Department of Urology, UC San Diego School of Medicine, La Jolla, CA. Electronic address:

Background: Treatment paradigms for management of metastatic renal cell carcinoma (mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in mRCC stratified by risk-group.

Methods: Multicenter retrospective analysis from the Registry of Metastatic RCC database. The cohort was subdivided utilizing Motzer criteria (favorable-, intermediate-, high-risk). Primary outcome was all-cause mortality (ACM)/overall survival (OS); secondary outcome was cancer-specific mortality (CSM)/cancer-specific survival (CSS). Impact of metastasectomy was analyzed via Cox-Regression analysis adjusting for potential prognostic variables and Kaplan-Meier analysis (KMA) within each risk-group.

Results: Four hundred thirty-one patients (59 favorable-risk, 274 intermediate-risk, 98 high-risk; median follow-up 27.2 months) were analyzed. Metastasectomy was performed in 22 (37%), 66 (24%), and 32 (16%) of favorable-, intermediate- and high-risk groups (P = .012). Median number of metastases at diagnosis differed significantly (favorable-risk 2, intermediate-risk 3.4, high-risk 5.1, P < .001). On Cox-regression, high-risk (HR = 1.72, P = .002) was associated with worsened ACM, while metastasectomy was associated with improved ACM (HR = 0.56, P = .005). On KMA, median OS (months) was longer with metastasectomy in favorable- (92.7 vs. 25.8, P = .003) and intermediate-risk (26.3 vs. 20.1, P = .038), but not high-risk (P = .911) groups. Metastasectomy was associated with longer CSS in favorable- (76.1 vs. 32.8, P = .004) but not intermediate- (P = .06) and high-risk (P = .595) groups.

Conclusions: Metastasectomy was independently associated with improved ACM and CSM, as well as improved CSS and OS in favorable- and intermediate-risk mRCC patients. Metastasectomy may be considered as component of multimodal management strategy in favorable and intermediate-risk subgroups. In high-risk patients, metastasectomy should be deferred except in select circumstances.

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.clgc.2022.03.013	DOI Listing

April 2022

Publication Analysis

Keyword Occurance

Similar Publications

Salvage living donor liver transplantation for post-resection recurrence of combined hepatocellular carcinoma-cholangiocarcinoma.

Authors:

Minjae Kim Shin Hwang Gi-Won Song Chul-Soo Ahn Deok-Bog Moon Dong-Hwan Jung Gil-Chun Park Sung-Gyu Lee

Korean J Transplant 2021 Jun 11;35(2):116-123. Epub 2021 Jan 11.

Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Salvage liver transplantation (LT) is a definite treatment for recurrent hepatocellular carcinoma (HCC) after hepatectomy. Combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) is not eligibly indicated for LT because of high post-transplant recurrence. We present a case of salvage living donor liver transplantation (LDLT) in a patient with tumor recurrence after surgical resection of cHCC-CC. Read More

View Article and Full-Text PDF

June 2021

Similar Publications

Metastasis to the Bladder: A Rare Site of Recurrence of Renal Cell Carcinoma.

Authors:

Amanda Smart Michael Wynne Ezra Baraban Yasser Ged Armine Smith

Case Rep Urol 2022 17;2022:4339270. Epub 2022 Jun 17.

The James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Renal cell carcinoma (RCC) is considered to be the deadliest urologic cancer with high rates of metastasis and recurrence after nephrectomy. RCC can metastasize to nearly any organ but most commonly metastasizes to the liver, lung, brain, and bone. To date, there are only about 40 reported cases of RCC with solitary bladder metastasis. Read More

View Article and Full-Text PDF

June 2022

Similar Publications

Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study.

Authors:

Tiuri E Kroese Sebastian M Christ Peter S N van Rossum Matthijs D L Burger George S Buijs Urs Mühlematter Nicolaus Andratschke Jelle P Ruurda Martin Hüllner Christian A Gutschow Richard van Hillegersberg Matthias Guckenberger

Radiother Oncol 2022 Jun 23. Epub 2022 Jun 23.

Department of Radiation Oncology, University Hospital Zurich, University Zurich, Switzerland. Electronic address:

Purpose /objective: This multicenter study assessed the incidence and survival of patients with esophagogastric cancer and oligometastatic disease (OMD) in two tertiary referral cancer centers in The Netherlands and Switzerland.

Materials /methods: Between 2010-2021, patients with metastatic esophagogastric cancer were identified. Patients with de-novo OMD were included (first-time diagnosis of ≤5 distant metastases on F-FDG-PET/CT). Read More

View Article and Full-Text PDF

June 2022

Similar Publications

Medium to Long-Term Clinical Outcomes of Spinal Metastasectomy.

Authors:

Satoshi Kato Satoru Demura Hideki Murakami Kazuya Shinmura Noriaki Yokogawa Ryohei Annen Motoya Kobayashi Yohei Yamada Satoshi Nagatani Norio Kawahara Hiroyuki Tsuchiya

Cancers (Basel) 2022 Jun 9;14(12). Epub 2022 Jun 9.

Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa 920-8641, Japan.

The prolonged survival of metastatic cancer patients highlights the importance of the local control of spinal metastases, which reduce patient performance status. This retrospective study examined the medium to long-term outcomes of spinal metastasectomy by evaluating 124 patients who underwent metastasectomy for isolated spinal metastases (2006-2018) with a postoperative follow-up for a minimum of 3 years. The findings present information on patient demographics (i. Read More

View Article and Full-Text PDF

June 2022

Similar Publications

Short-term outcomes of neoadjuvant chemotherapy with capecitabineplus oxaliplatin for patients with locally advanced rectal cancerfollowed by total or tumor-specific mesorectal excision with orwithout lateral pelvic lymph node dissection.

Authors:

Wataru Sakamoto Yasuyuki Kanke Hisashi Onozawa Hirokazu Okayama Hisahito Endo Shotaro Fujita Motonobu Saito Zenichiro Saze Tomoyuki Momma Koji Kono

Fukushima J Med Sci 2022 Jun 23. Epub 2022 Jun 23.

Department of Gastrointestinal Tract Surgery, School of Medicine, Fukushima Medical University.

Background: The standard strategy in Japan for locally advanced rectal cancer is total mesorectal excision plus adjuvant chemotherapy. However, large tumors significantly restrict pelvic manipulation of the distal side of the tumor during surgery;therefore, from an oncological point of view, it is better to shrink the tumor as much as possible preoperatively to optimize the circumferential resection margin. In recent years, advances in systemic chemotherapy have significantly improved the tumor reduction effect, enabling such drug therapy prior to surgery for locally advanced rectal cancer. Read More

View Article and Full-Text PDF

June 2022

Similar Publications

}

Search Our Scientific Publications & Authors